ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP in Immune Cell Cryopreservation Testing Business Wire "Press Releases - English"
ST. MARYS, W. Va. --(BUSINESS WIRE)-- ProtoKinetix , Incorporated (OTC: PKTX) (the "Company" or " ProtoKinetix ") (www.protokinetix.com) and Proactive Immune Sciences (www.proactiveimmunesciences.com) today announce that they have entered into a joint research collaboration. The goal of the research will be to test the effect of the patented anti-aging glycopeptide AAGP on the immune cell cryopreservation protocols used by Proactive Immune Sciences.
We are excited about this new joint research collaboration and hope AAGP has some of the same positive effects, with respect to cryopreserving immune cells, that it is having on other cell lines, says Jeff Schulz , CEO, Proactive Immune Sciences. We are hoping to prove through our research that AAGP will have a positive affect on helping immune cells recover from the cryopreservation process. Any improvement in cell survival rate, or cell function could have significant, positive benefits for future treatments using cryopreserved immune cells.
Pending a successful outcome of our research, the intent is for Proactive to enter into a licensing agreement with ProtoKinetix for the cryopreservation of immune cells. This will give Proactive customers the benefit of knowing their stored immune cells will perform at the highest levels possible should they require them for any immune cell based cancer or immune system reconstitution later in their life.
About Immune Cell Banking
The initial phase of the research is expected to conclude later in 2017. Partial funding for the project has been provided by The National Research Councils Industrial Research Assistance Program .
About the National Research Council's Industrial Research Assistance Program
Immune based interventions represent one of the fastest growing, most promising areas of personalized medicine. This is particularly true for cancer, which is largely a disease of immune failure. Therefore, there is a strong impetus for individuals to bank healthy immune cells at as early an age as possible, before these cells are compromised by infection, malignancy, or simply advanced immunological age. These cells can be used later on for any form of immunotherapy the client might require.
We welcome the opportunity to show the effectiveness of our AAGP molecule in another rapidly expanding, high-demand, commercial arena, further demonstrating the versatility of this molecules ability to protect cells in different clinical situations, said Clarence Smith , President, CEO and Chairman of the Board of ProtoKinetix .
